Literature DB >> 23438833

Diabetes: Blocking RANKL signalling might prevent T2DM.

Carol Wilson.   

Abstract

Entities:  

Year:  2013        PMID： 23438833     DOI： 10.1038/nrendo.2013.43

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.

Authors:  Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440
  1 in total
  1 in total

1.  Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis.

Authors:  Blanca T Pacheco-Soto; Rebeca Garazi Elguezabal-Rodelo; Leonardo M Porchia; Enrique Torres-Rasgado; Ricardo Pérez-Fuentes; M Elba Gonzalez-Mejia
Journal:  J Drug Assess       Date:  2021-10-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.